BioCryst Historical Financial Ratios
| BCRX Stock | USD 7.53 0.07 0.92% |
BioCryst Pharmaceuticals is presently reporting on over 109 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, Days Sales Outstanding of 59.59 or Invested Capital of 0.0 will help investors to properly organize and evaluate BioCryst Pharmaceuticals financial condition quickly.
BioCryst |
About BioCryst Financial Ratios Analysis
BioCryst PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate BioCryst Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on BioCryst financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across BioCryst Pharmaceuticals history.
BioCryst Pharmaceuticals Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing BioCryst Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on BioCryst Pharmaceuticals sales, a figure that is much harder to manipulate than other BioCryst Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Stock Based Compensation To Revenue
A metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Effective Tax Rate
Effective Tax Rate is the average rate at which BioCryst Pharmaceuticals pre-tax profits are taxed by the government. The effective tax rate is computed by dividing BioCryst Pharmaceuticals total tax expenses by BioCryst Pharmaceuticals earnings before taxes.Most ratios from BioCryst Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into BioCryst Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.At this time, BioCryst Pharmaceuticals' Average Payables is fairly stable compared to the past year. Days Of Inventory On Hand is likely to rise to 2,358 in 2024, whereas Price To Sales Ratio is likely to drop 3.30 in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Graham Number | 12.48 | 15.3 | 7.93 | 6.31 | Receivables Turnover | 5.34 | 5.35 | 5.82 | 2.98 |
BioCryst Pharmaceuticals fundamentals Correlations
Click cells to compare fundamentals
BioCryst Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
BioCryst Pharmaceuticals fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 8.17 | 69.96 | 15.78 | 7.88 | 3.47 | 3.3 | |
| Ptb Ratio | (1.14) | (0.47) | (1.22) | (2.05) | (2.53) | (2.4) | |
| Days Sales Outstanding | 165.52 | 177.17 | 68.31 | 68.19 | 62.72 | 59.59 | |
| Operating Cash Flow Per Share | (0.77) | (0.82) | (0.79) | (0.87) | (0.5) | (0.52) | |
| Stock Based Compensation To Revenue | 0.5 | 0.45 | 0.36 | 0.83 | 0.22 | 0.17 | |
| Pb Ratio | (1.14) | (0.47) | (1.22) | (2.05) | (2.53) | (2.4) | |
| Ev To Sales | 7.56 | 61.68 | 16.35 | 9.49 | 5.7 | 5.42 | |
| Free Cash Flow Per Share | (0.9) | (0.78) | (0.82) | (0.81) | (0.88) | (0.51) | |
| Inventory Turnover | 0.29 | 2.64 | 0.24 | 0.46 | 0.16 | 0.15 | |
| Net Income Per Share | (0.98) | (1.04) | (1.18) | (1.03) | (1.33) | (1.24) | |
| Days Of Inventory On Hand | 138.04 | 1.5K | 793.46 | 1.5K | 2.2K | 2.4K | |
| Payables Turnover | 0.29 | 0.0896 | 0.26 | 0.46 | 0.22 | 0.21 | |
| Research And Ddevelopement To Revenue | 2.19 | 6.9 | 1.33 | 0.94 | 0.65 | 0.62 | |
| Capex To Revenue | 0.007024 | 0.0289 | 0.0152 | 0.004988 | 0.006542 | 0.006215 | |
| Cash Per Share | 1.18 | 1.8 | 2.83 | 2.28 | 2.02 | 2.13 | |
| Pocfratio | (4.45) | (9.08) | (17.45) | (13.19) | (12.1) | (12.71) | |
| Interest Coverage | (8.36) | (12.05) | (3.0) | (1.5) | (0.96) | (1.01) | |
| Capex To Operating Cash Flow | (0.003829) | (0.003746) | (0.0168) | (0.008347) | (0.0228) | (0.0239) | |
| Pfcf Ratio | (4.43) | (9.05) | (17.16) | (13.08) | (11.83) | (12.42) | |
| Days Payables Outstanding | 1.2K | 4.1K | 1.4K | 794.65 | 1.6K | 1.6K | |
| Income Quality | 0.82 | 0.75 | 0.77 | 0.65 | 0.42 | 0.4 | |
| Ev To Operating Cash Flow | (4.12) | (8.01) | (18.08) | (15.88) | (19.86) | (20.85) | |
| Pe Ratio | (3.32) | (6.34) | (13.48) | (8.64) | (5.08) | (5.34) | |
| Ev To Free Cash Flow | (4.11) | (7.98) | (17.78) | (15.75) | (19.42) | (20.39) | |
| Net Debt To E B I T D A | 0.31 | 0.88 | (0.73) | (3.04) | (6.34) | (6.03) | |
| Current Ratio | 1.78 | 3.06 | 5.46 | 4.9 | 3.31 | 3.14 | |
| Receivables Turnover | 2.21 | 2.06 | 5.34 | 5.35 | 5.82 | 2.98 | |
| Graham Number | 13.04 | 12.72 | 12.48 | 15.3 | 7.93 | 6.31 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.